Patient-partnered drug discovery: vision or reality?

Views & Analysis
Patient-partnered-drug-discovery-vision-or-reality-1200x675-Feature

pharmaphorum’s Paul Tunnah talks to Anthony Yanni, newly appointed senior vice president & global head of patient centricity, Astellas, about why partnering with patients is the cornerstone for change throughout the drug development lifecycle – from early discovery through to market. Here he reveals how, in his new role, he will use this defining principle to reshape the very foundations of the organisation.

What do you think when you read the words ‘patient centricity’?

While few can dispute the inherent sense behind pharma shouting about patient centricity from the rooftops, this sentiment has – until now – lacked authenticity and many companies have failed to define how having a patient-first focus is either commercially beneficial or sustainable.

Now, however, enlightened companies are waking up to the reality that ‘nice to have’ has become ‘must have’ and are putting patient centricity firmly front and centre of their future vision and strategy.

• Read the full article in pharmaphorum's Deep Dive digital magazine